[Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
The translation of quantitative polymerase chain reaction technology for the quantitative detection of minimal residual disease (MRD) arising from molecular aberrations in leukaemias has progressed from the pre-clinical setting to daily clinical practice. Thus, it is now part of the mainstay in following patients with chronic myeloid leukaemia treated with the tyrosine kinase inhibitor imatinib. Moreover, the methodology is being integrated in an increasing number of clinical trials, where it is expected to result in more rational and individualized clinical decision-making. A special point in favour of the techniques is the powerful and early detection of disease relapses, in some cases up to one year prior to clinical detection.
Hokland
Peter
P
Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C. phokland@ki.au.dk
Ommen
Hans Beier
HB
Nyvold
Charlotte Guldborg
CG
Stentoft
Jesper
J
Braendstrup
Karin
K
Andersen
Bodil Lind
BL
Mikkelsen
Lone Siig
LS
Ostergaard
Mette
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000032:analysis; D055088:Early Detection of Cancer; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate